On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.

In July 2020, Viwit Pharmaceuticals’ Aprepitant was granted a Certificate of Suitability (CEP) by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Following this, in July 2021, Viwit Pharmaceuticals also obtained a drug license from the Taiwan Ministry of Health and Welfare (TFDA). These successive approvals by multiple regulatory agencies validate Viwit Pharmaceuticals' adherence to the development and manufacturing compliance of the global standards.

Aprepitant, a neurokinin-1 (NK-1) receptor antagonist, is a recommended medication for preventing nausea and vomiting induced by highly emetogenic anticancer chemotherapies. It is available in several dosage forms including capsules, injections, and oral suspensions. In 2022, the sales of Aprepitant capsules in Chinese public healthcare institutions exceeded 100 million dollars.